Compare FIZZ & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIZZ | TVTX |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | 497 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.8B |
| IPO Year | 1994 | 2013 |
| Metric | FIZZ | TVTX |
|---|---|---|
| Price | $34.15 | $42.53 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $35.00 | ★ $40.62 |
| AVG Volume (30 Days) | 167.2K | ★ 2.3M |
| Earning Date | 03-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.29 | ★ 92.89 |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $1,201,354,000.00 | N/A |
| Revenue This Year | $0.14 | $44.76 |
| Revenue Next Year | $3.33 | $35.51 |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $31.21 | $13.88 |
| 52 Week High | $47.88 | $43.31 |
| Indicator | FIZZ | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 67.69 |
| Support Level | $32.58 | $32.62 |
| Resistance Level | $35.86 | N/A |
| Average True Range (ATR) | 0.73 | 1.97 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 54.05 | 92.10 |
National Beverage Corp is a non-alcoholic beverage company in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls the majority of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for retailers, direct-store delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants).
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.